ARRA::YES::ARRA TAS::75 0850::TAS RECOVERY ACT - TISSUE SOURCE SITE (TSS) IN SUP

ARRA::是::ARRA TAS::75 0850::TAS 恢复法案 - SUP 中的组织源站点 (TSS)

• 批准号: 8166068
• 负责人: JILL BARNHOLTZ-SOLOAN
• 金额: $ 71.54万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-28 至 2012-02-23
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166068
• 关键词: Atlases; Blood; Cell Nucleus; Clinical Data; Collection; Consent; Contractor; Copy Number Polymorphism; DNA; Data; Diagnosis; Enrollment; Ensure; Excision; Freezing; Genes; Institution; MicroRNAs; Molecular; Mutation Analysis; Necrosis; Patients; Process; Protocols documentation; Qualifying; Quality Control; Recovery; Research; Resources; Sampling; Series; Shipping; Ships; Single Nucleotide Polymorphism; Site; Source; Time; Tissues; biobank; cancer diagnosis; cancer genome; clinical research site; epigenomics; follow-up; programs; prospective; tumor

TCGA has historically relied on retrospectively collected biospecimens. These tissues were accrued by dozens of TSSs around the world through a series of subcontracts managed through the prime contractor at SAIC-Frederick. TSSs included clinical sites, academic institutions as well as commercial companies with biorepositories. Retrospective samples have been invaluable sources of tissue and clinical data, often including long term follow-up. However, the rigorous biospecimen quality, including amount of tissue needed (between 100-150mg), percent of tumor nuclei (at least 70%) and low amount of necrosis (less than 30%) has posed challenges, requiring TCGA to look also at prospective collections. The purpose of this project is to establish Tissue Source Site (TSS) networks capable of delivering clinically annotated biospecimens through either/both retrospective and prospective collections. The tissues and clinical data will be delivered to one of TCGA¿s Biospecimen Core Resource(s) (BCR) for storage, quality control, processing into molecular analytes, and other research efforts. Ultimately, the samples will be characterized for copy number variation, single nucleotide polymorphisms, epigenomic profiles, gene and miRNA expression and mutation analysis.

TCGA历史上一直依赖回顾性收集的生物测量。这些时间是通过Saic-Frederick的总理承包商管理的一系列分包合同，由世界各地的数十个TSS累积。 TSS包括临床站点，学术机构以及具有生物焦点的商业公司。回顾性样本已经是组织和临床数据的宝贵来源，通常包括长期随访。然而，严格的生物测量质量，包括所需的组织数量（100-150mg），肿瘤核的百分比（至少70％）和坏死量（少于30％）是针对性的挑战，要求TCGA也必须考虑预期收集。该项目的目的是建立能够通过回顾性收集和前瞻性收集来提供临床注释的生物传感器的组织源站点（TSS）网络。组织和临床数据将传递到TCGA？S Biospecimen Core资源之一（S）（BCR）之一，用于存储，质量控制，处理分子分析以及其他研究工作。最终，将对样品进行拷贝数变化，单核肽多态性，表观基因组谱，基因和miRNA表达和突变分析的特征。